⌘K
t
On October 23, 2023, Nuformix plc announced it received an Official Decision to Grant Notice of Allowance for Japanese National Phase Patent Application No. 2020-555115. This patent is entitled "CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE" and relates to the Company's NXP002 asset.
| Date | 23 Oct 2023 |
| Time | 07:00:11 |
| Category | Miscellaneous |
| ID | 8813Q |
23 October 2023
Nuformix plc
("Nuformix" or the "Company")
Notice of Allowance of NXP002 Patent in Japan
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that it has been issued with an Official Decision to Grant Notice of Allowance for Japanese National Phase Patent Application No. 2020-555115 entitled "CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE".
NXP002 is the Company's lead asset and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF"). The granted patent describes a proprietary new form of the drug tranilast, uniquely enabling delivery via an inhaled nebulised formulation. Nuformix owns two patent applications relating to crystalline forms of tranilast, one of which had already been granted globally. This second patent application, which as has already been granted in the US, specifically addresses the novel tranilast forms being progressed by the Company as a potential novel IPF treatment.
Dr Dan Gooding, Executive Director of Nuformix, said: "I'm delighted we have received this Official Decision to Grant from the Japanese Patent Office. This provides confirmation that no prior art exists in relation to NXP002, which is very important given that this is the territory in which tranilast was first invented and where the vast majority of considerable subsequent development work has been conducted. The grant is therefore an important step forward for our lead asset NXP002. We expect the European grant to follow shortly, which will further support the Company's on-going partnering activities."
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director
|
Via IFC Advisory
|
|
Stanford Capital Partners Limited |
|
|
Tom Price / Patrick Claridge (Corporate Finance) |
+44 (0) 20 3650 3650 |
|
John Howes (Corporate Broking) |
+44 (0) 20 3650 3652
|
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.